# Hyliion Holdings Corp.: financial statements, quarterly

HYLN · NYSE · CIK 1759631 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hyln.md) · [Financials](/companies/hyln/financials.md) · [Filings](/companies/hyln/filings.md) · [Insiders](/companies/hyln/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hyln/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001759631-24-000181.md) | [0.0 d](/filings/0001759631-25-000051.md) | [0.0](/filings/0001759631-25-000088.md) | [0.0](/filings/0001759631-25-000132.md) | [0.0](/filings/0001628280-25-051326.md) | [1.5 d](/filings/0001628280-26-011278.md) | [0.5](/filings/0001628280-26-034116.md) | [1.5](/filings/0001628280-26-055738.md) | [0.8](/filings/0001628280-25-051326.md) | [0.7 d](/filings/0001628280-26-011278.md) | [2.8](/filings/0001628280-26-034116.md) | [4.9](/filings/0001628280-26-055738.md) |
| Cost of revenue | $m | [0.7](/filings/0001759631-24-000181.md) | [0.0 d](/filings/0001759631-25-000051.md) | [0.0](/filings/0001759631-25-000088.md) | [0.0](/filings/0001759631-25-000132.md) | [0.0](/filings/0001628280-25-051326.md) | [1.4 d](/filings/0001628280-26-011278.md) | [0.5](/filings/0001628280-26-034116.md) | [1.4](/filings/0001628280-26-055738.md) | [0.8](/filings/0001628280-25-051326.md) | [0.6 d](/filings/0001628280-26-011278.md) | [2.6](/filings/0001628280-26-034116.md) | [4.6](/filings/0001628280-26-055738.md) |
| Gross profit | $m | [(0.6)](/filings/0001759631-24-000181.md) | [(0.0) d](/filings/0001759631-25-000051.md) | [0.0](/filings/0001759631-25-000088.md) | [0.0](/filings/0001759631-25-000132.md) | [0.0](/filings/0001628280-25-051326.md) | [0.1 d](/filings/0001628280-26-011278.md) | [0.0](/filings/0001628280-26-034116.md) | [0.1](/filings/0001628280-26-055738.md) | [(0.0)](/filings/0001628280-25-051326.md) | [0.1 d](/filings/0001628280-26-011278.md) | [0.2](/filings/0001628280-26-034116.md) | [0.4](/filings/0001628280-26-055738.md) |
| Research and development | $m | [25.1](/filings/0001759631-24-000181.md) | [8.8 d](/filings/0001759631-25-000051.md) | [8.0](/filings/0001759631-25-000088.md) | [8.3](/filings/0001759631-25-000132.md) | [9.5](/filings/0001628280-25-051326.md) | [11.3 d](/filings/0001628280-26-011278.md) | [12.2](/filings/0001628280-26-034116.md) | [10.1](/filings/0001628280-26-055738.md) | [10.1](/filings/0001628280-25-051326.md) | [10.0 d](/filings/0001628280-26-011278.md) | [7.7](/filings/0001628280-26-034116.md) | [9.5](/filings/0001628280-26-055738.md) |
| Selling, general and administrative | $m | [8.2](/filings/0001759631-24-000181.md) | [12.3 d](/filings/0001759631-25-000051.md) | [6.6](/filings/0001759631-25-000088.md) | [6.3](/filings/0001759631-25-000132.md) | [5.6](/filings/0001628280-25-051326.md) | [5.9 d](/filings/0001628280-26-011278.md) | [6.1](/filings/0001628280-26-034116.md) | [6.0](/filings/0001628280-26-055738.md) | [5.2](/filings/0001628280-25-051326.md) | [5.5 d](/filings/0001628280-26-011278.md) | [6.2](/filings/0001628280-26-034116.md) | [6.4](/filings/0001628280-26-055738.md) |
| Operating income | $m | [(33.9)](/filings/0001759631-24-000181.md) | [(32.6) d](/filings/0001759631-25-000051.md) | [(19.0)](/filings/0001759631-25-000088.md) | [(14.0)](/filings/0001759631-25-000132.md) | [(14.2)](/filings/0001628280-25-051326.md) | [(17.1) d](/filings/0001628280-26-011278.md) | [(19.7)](/filings/0001628280-26-034116.md) | [(15.6)](/filings/0001628280-26-055738.md) | [(15.3)](/filings/0001628280-25-051326.md) | [(14.9) d](/filings/0001628280-26-011278.md) | [(13.2)](/filings/0001628280-26-034116.md) | [(15.3)](/filings/0001628280-26-055738.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(30.3)](/filings/0001759631-24-000181.md) | [(29.1) d](/filings/0001759631-25-000051.md) | [(15.6)](/filings/0001628280-25-051326.md) | [(10.9)](/filings/0001628280-25-051326.md) | [(11.2)](/filings/0001628280-25-051326.md) | [(14.4) d](/filings/0001628280-26-011278.md) | [(17.3)](/filings/0001628280-26-055738.md) | [(13.4)](/filings/0001628280-26-055738.md) | [(13.3)](/filings/0001628280-25-051326.md) | [(13.2) d](/filings/0001628280-26-011278.md) | [(11.7)](/filings/0001628280-26-055738.md) | [(13.9)](/filings/0001628280-26-055738.md) |
| Diluted EPS | $ per share | [(0.17)](/filings/0001759631-24-000181.md) | not reported | [(0.09)](/filings/0001759631-25-000088.md) | [(0.06)](/filings/0001759631-25-000132.md) | [(0.06)](/filings/0001628280-25-051326.md) | not reported | [(0.10)](/filings/0001628280-26-034116.md) | [(0.08)](/filings/0001628280-26-055738.md) | [(0.08)](/filings/0001628280-25-051326.md) | not reported | [(0.07)](/filings/0001628280-26-034116.md) | [(0.08)](/filings/0001628280-26-055738.md) |
| Basic EPS | $ per share | [(0.17)](/filings/0001759631-24-000181.md) | not reported | [(0.09)](/filings/0001759631-25-000088.md) | [(0.06)](/filings/0001759631-25-000132.md) | [(0.06)](/filings/0001628280-25-051326.md) | not reported | [(0.10)](/filings/0001628280-26-034116.md) | [(0.08)](/filings/0001628280-26-055738.md) | [(0.08)](/filings/0001628280-25-051326.md) | not reported | [(0.07)](/filings/0001628280-26-034116.md) | [(0.08)](/filings/0001628280-26-055738.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [28.6](/filings/0001759631-23-000095.md) | [12.9](/filings/0001759631-25-000051.md) | [14.7](/filings/0001759631-24-000089.md) | [19.1](/filings/0001759631-24-000127.md) | [28.1](/filings/0001759631-24-000181.md) | [9.2](/filings/0001628280-26-055738.md) | [12.3](/filings/0001759631-25-000088.md) | [15.6](/filings/0001628280-26-055738.md) | [17.9](/filings/0001628280-25-051326.md) | [22.9](/filings/0001628280-26-055738.md) | [20.3](/filings/0001628280-26-034116.md) | [13.2](/filings/0001628280-26-055738.md) |
| Current assets | $m | [194](/filings/0001759631-23-000095.md) | [182](/filings/0001759631-25-000051.md) | [154](/filings/0001759631-24-000089.md) | [165](/filings/0001759631-24-000127.md) | [161](/filings/0001759631-24-000181.md) | [131](/filings/0001628280-26-011278.md) | [128](/filings/0001759631-25-000088.md) | [115](/filings/0001759631-25-000132.md) | [110](/filings/0001628280-25-051326.md) | [98.6](/filings/0001628280-26-055738.md) | [81.4](/filings/0001628280-26-034116.md) | [71.6](/filings/0001628280-26-055738.md) |
| Total assets | $m | [356](/filings/0001759631-23-000095.md) | [328](/filings/0001759631-25-000051.md) | [298](/filings/0001759631-24-000089.md) | [281](/filings/0001759631-24-000127.md) | [272](/filings/0001759631-24-000181.md) | [263](/filings/0001628280-26-011278.md) | [241](/filings/0001759631-25-000088.md) | [229](/filings/0001759631-25-000132.md) | [216](/filings/0001628280-25-051326.md) | [204](/filings/0001628280-26-055738.md) | [191](/filings/0001628280-26-034116.md) | [180](/filings/0001628280-26-055738.md) |
| Current liabilities | $m | [13.2](/filings/0001759631-23-000095.md) | [15.1](/filings/0001759631-25-000051.md) | [10.5](/filings/0001759631-24-000089.md) | [7.5](/filings/0001759631-24-000127.md) | [9.2](/filings/0001759631-24-000181.md) | [14.3](/filings/0001628280-26-011278.md) | [9.2](/filings/0001759631-25-000088.md) | [10.3](/filings/0001759631-25-000132.md) | [10.0](/filings/0001628280-25-051326.md) | [9.9](/filings/0001628280-26-055738.md) | [8.1](/filings/0001628280-26-034116.md) | [9.4](/filings/0001628280-26-055738.md) |
| Total liabilities | $m | [21.8](/filings/0001759631-23-000095.md) | [22.1](/filings/0001759631-25-000051.md) | [17.2](/filings/0001759631-24-000089.md) | [13.5](/filings/0001759631-24-000127.md) | [14.6](/filings/0001759631-24-000181.md) | [18.7](/filings/0001628280-26-011278.md) | [13.0](/filings/0001759631-25-000088.md) | [13.3](/filings/0001759631-25-000132.md) | [12.4](/filings/0001628280-25-051326.md) | [11.6](/filings/0001628280-26-055738.md) | [9.0](/filings/0001628280-26-034116.md) | [10.1](/filings/0001628280-26-055738.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [334](/filings/0001759631-24-000181.md) | [306](/filings/0001628280-26-011278.md) | [280](/filings/0001628280-25-051326.md) | [268](/filings/0001628280-25-051326.md) | [258](/filings/0001628280-25-051326.md) | [244](/filings/0001628280-26-055738.md) | [228](/filings/0001628280-26-055738.md) | [216](/filings/0001628280-26-055738.md) | [204](/filings/0001628280-25-051326.md) | [192](/filings/0001628280-26-055738.md) | [182](/filings/0001628280-26-055738.md) | [170](/filings/0001628280-26-055738.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(28.8) d](/filings/0001759631-24-000181.md) | [(24.5) d](/filings/0001759631-25-000051.md) | [(22.7)](/filings/0001759631-25-000088.md) | [(10.7) d](/filings/0001759631-25-000132.md) | [(9.9) d](/filings/0001628280-25-051326.md) | [(13.4) d](/filings/0001628280-26-011278.md) | [(14.0)](/filings/0001628280-26-034116.md) | [(10.0) d](/filings/0001628280-26-055738.md) | [(10.7) d](/filings/0001628280-25-051326.md) | [(11.9) d](/filings/0001628280-26-011278.md) | [(12.7)](/filings/0001628280-26-034116.md) | [(7.1) d](/filings/0001628280-26-055738.md) |
| Capital expenditure | $m | [2.8 d](/filings/0001759631-24-000181.md) | [0.6 d](/filings/0001759631-25-000051.md) | [2.8](/filings/0001759631-25-000088.md) | [5.2 d](/filings/0001759631-25-000132.md) | [2.5 d](/filings/0001628280-25-051326.md) | [6.0 d](/filings/0001628280-26-011278.md) | [7.3](/filings/0001628280-26-034116.md) | [4.2 d](/filings/0001628280-26-055738.md) | [10.4 d](/filings/0001628280-25-051326.md) | [1.7 d](/filings/0001628280-26-011278.md) | [1.9](/filings/0001628280-26-034116.md) | [0.2 d](/filings/0001628280-26-055738.md) |
| Share repurchases | $m | [0.0 d](/filings/0001759631-24-000181.md) | [0.0 d](/filings/0001759631-25-000051.md) | [11.0](/filings/0001759631-25-000088.md) | [2.9 d](/filings/0001759631-25-000132.md) | [0.0 d](/filings/0001628280-25-051326.md) | [0.0 d](/filings/0001628280-26-011278.md) | [0.0](/filings/0001759631-25-000088.md) | [0.0 d](/filings/0001759631-25-000132.md) | [0.0 d](/filings/0001628280-25-051326.md) | [0.0 d](/filings/0001628280-26-011278.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [174](/filings/0001759631-23-000095.md) | [180](/filings/0001759631-24-000089.md) | [181](/filings/0001759631-24-000127.md) | [182](/filings/0001759631-24-000181.md) | [178](/filings/0001759631-25-000088.md) | [174](/filings/0001759631-25-000132.md) | [174](/filings/0001628280-25-051326.md) | [174](/filings/0001628280-26-034116.md) | [175](/filings/0001628280-26-055738.md) | [176](/filings/0001628280-25-051326.md) | [178](/filings/0001628280-26-034116.md) | [178](/filings/0001628280-26-055738.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 178,597,218 at 2026-08-03, from the cover of the [10-Q filed 2026-08-11](/filings/0001628280-26-055738.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.